Original Article

Quantitative estimation of Eflornithine by Nitrite (Diazotization) titration

Amit Kumar^{a,*}, Vijender Singh^b, Praveen Kumar^c

^aTeerthankar Mahaveer University, (TMU), Teerthanker Mahaveer College of Pharmacy, Moradabad, Uttar Pradesh, India. ^bBBS Institute of Pharmaceutical & Allied Sciences, Greater Noida, India. ^cMoradabad Educational Trust Group of Institutions Faculty of Pharmacy, Moradabad, Uttar Pradesh, India.

*Corresponding Author. Tel.: +9897144639, E-mail address: amit81ak@gmail.com

ARTICLE INFO

Received 27 Nov 2015 Revised 17 Dec 2015 Accepted 21 Dec 2015

Keywords:

- Eflornithine hydrochloride
- Nitrite Titration
- Diazonium salt
- Indicator
- End point

ABSTRACT

Effornithine hydrochloride (DFMO) being a primary aliphatic amine reacts with the nitrous acid (in situ liberation by the reaction of ice cold sodium nitrite and hydrochloric acid) and gets converted to diazonium salt. At the end point an excess drop of titrant sodium nitrite from the burette liberates nitrous acid; this free acid is determined by the starch-mucilage paper, used as an external indicator. The free nitrous acid reacts with potassium iodide and reduces the iodide to free iodine, which produces intense blue color with the alpha-amylose portion of the starch indicating the end point. The Effornithine hydrochloride (DFMO, Difluoromethylornithine) determined by Diazotization Titration (DAT M-01). Here the amino group of Effornithine is diazotized with sodium nitrite solution in cold acid solution. The nitrous acid formed diazotizes the compound. The iodine formed reacts with starch mucilage to give the blue color. The percentage of purity in DFMO is found 99.74%.

1. INTRODUCTION

Eflornithine, DL-alpha-difluoromethylornithine (DFMO; Ornidyl) is a selective, irreversible inhibitor of ornithine decarboxylase enzyme and one of the key enzymes in the polyamine biosynthetic pathway [1,2]. The drug is originally developed to use in cancer and in phase III clinical trials for preventing recurrence of superficial bladder cancer. It has been used as antiprotozoal agent in the treatment of meningoencephalic stage of trypanosomiasis caused by Trypanosoma brucei gambienze (African trypanosomiasis) [3, 4, 5]. It is now licensed for use in sleeping sickness in USA, Europe and twelve African countries [6,7]. In African trypanosomiasis, DFMO has been approved by the FDA, USA for the treatment of the meningoencephalic stage [8, 9]. DFMO currently used in development and testing for its anti-inflammatory activity [10]. DFMO 13.9% cream is used to inhibit growth and reduce the amount of facial hair in women [11, 12]. The drug development

process of DFMO in these diseases is currently at a relatively early stage and therefore the full pharmacokinetic characterization in patients, in conjunction with pharmacodynamics (clinical efficacy/safety) is essential for optimization of drug therapy.

A number of analytical methods have been reported for measuring DFMO in biological fluids and tissue extracts. These methods involved HPLC techniques [13,14,15]. The HPLC techniques currently available for the quantification of DFMO in biological fluids involve either pre or post column derivatization with UV or fluorescence detection [16] and LC carried out by evaporative light scattering detection.

A reverse HPLC method utilizing pre-column dansylation is described for the analysis of DFMO in serum. Derivatization is necessary at least 04 hrs is necessary for maximum derivative formation. All the above mentioned methods are either long procedures or require sophisticated sample preparation or chromatographic procedures [13,14,15,17,18].

2. EXPERIMENTAL

2.1 Material and Methods

All the solvents and chemicals were of analytical reagent grade and were supplied by Sigma-Aldrich and Qualigens fine chemicals, India. Effornithine hydrochloride is marketed under the trade name Ornidyl. Each sample (Ornidyl) vial (SVP) is containing 200 mg/ml. The pure drug (DFMO) was gifted by Wintac Limited, Bangalore, India. Distilled water was used through this study.

2.2 Preparation and standardization of 0.1 M Sodium Nitrite solution

7.5 gm of sodium nitrite is dissolved in sufficient water to produed 1000 ml and is standardized. About 0.5 gm of sulphanilamide, previously dried at 105°C for three hours is transferred to a suitable beaker. 50 ml of water and 20 ml of hydrochloric acid is added, stirred until it dissolves and cooled to 5°C. The contents of the beaker are titrated against 0.1M sodium nitrite solution [19]. The standardization reaction of nitrite titration is shown in Fig. 1.



Fig. 1. Standardization reaction of nitrite titration

2.3 Estimation of % purity of Eflornithine (DFMO)

Weigh accurately 0.5234 g DFMO and transferred into a conical flask, dissolved in about 25 ml of water and 15 ml of 2 M hydrochloric acid and cool to about 5°C. The mixture is titrated against 0.1M sodium nitrite solution by using external indicator as starch iodide solution until blue color appears. Each ml of 0.1M sodium nitrite solution is equivalent to 0.021865 g of DFMO. The volume of 0.1M sodium nitrite solution 26.53 ml (average volume of three readings) is consumed by 0.5234 g DFMO (Average weight of three weighing). The % Purity of Eflornithine is found 99.74%, indicated the robustness of the method.

2.4 Assay Reaction of Nitrite Titration

DFMO being a primary aliphatic amine reacts with the nitrous acid (in situ liberation by the reaction of ice cold sodium nitrite and hydrochloric acid) and gets converted to diazonium salt. At the end point an excess drop of titrant sodium nitrite from the burette liberates nitrous acid; this free acid is determined by the starch-mucilage paper, used as an external indicator. The free nitrous acid reacts with potassium iodide and reduces the iodide to free iodine, which produces intense blue color with the alphaamylose portion of the starch indicating the end point. The assay reaction of nitrite titration is shown in Fig. 2.



Diazonium salt

KI + HCl \longrightarrow KCl + HI Starch $I_2 + 2NO + 2H_2O$ mucilage (Blue Color)

Fig. 2. Assay reaction of the nitrite titration.

3. RESULTS AND DISCUSSION

Reaction mechanism of diazotization titration

Titrant: standardized 0.1N NaNO,

Conical Flask: acidified solution of DFMO NaNO₂ + HCl → HNO₂ + NaCl



Fig. 3. Assay reaction mechanism of Eflornithine.

Sodium nitrate reacts with the hydrochloric acid to produce the nitrous acid (in situ), which in turn generates the nitrosyl ion. This nitrosyl ion being an electrofile, it attaches to the electron rich primary amino group of the DFMO (nitrogen of the primary amino group contains the lone pair electrons) to form the N-nitrosyl derivative, which rearranges to form resonance stabilized diazonium salt after the elimination of water molecule. (Inductive effect coupled with the electro-negativity of the both oxygen of the carboxylic acid group and the fluorine of the difluoro methyne group influences the attack of the nitrosyl group with the amino group, thus the amino group of the carbon bearing both amino and carboxylic acid group is preferably attacked). At the end point an excess drop of sodium nitrite produces the nitrous acid; this will react with the potassium iodide to produce the iodine which is detected by the starch mucilage paper used as the external indicator. The assay reaction mechanism of Effornithine (DFMO) is shown in Fig. 3.

4. CONCLUSION

In this study, we have successfully developed a new novel nitrite method for the determination of DFMO in its dosage form. The method is sensitive, selective, rapid and economical for routine analysis. Furthermore, the entire analytical reagents are inexpensive, have excellent shelf life, and are available in any analytical laboratory. The method is practically and valuable for routine application in quality control laboratories for analysis of DFMO.

Acknowledgements

First author is highly thankul to IFTM University, Moradabad, India for Ph.D. registration and facilities. We thank to Wintac Pvt. Ltd. Bangalore, India, for providing a sample of DFMO as a gift.

REFERENCES

- Bacchi, C.J.; Goldberg, B.; Garofalo-Hannan, J.; Rattendi, D.; Lyte, P.; Yarlett, N. Fate of soluble methionine in African trypanosomes: effects of metabolic inhibitors. *Biochem. J.* 1995, 309(3), 737-43.
- [2] Bitonti, A.J.; Bacchi, C.J.; McCann, P.P.; Sjoerdsma, A. Catalytic irreversible inhibition of Trypanosoma brucei brucei ornithine decarboxylase by substrate and product analogs and their effects on murine trypanosomiasis. *Biochem. Pharmacol.* 1985, 34(10), 1773-1777.
- [3] McCann, P.P.; Bacchi, C.J.; Clarkson, A.B.; Jr Seed, J.R.; Nathan, H.C.; Amole, B.O.; Hutner, S.H.; Sjoerdsma, A. Further studies on difluoromethylornithine in African trypanosomes. *Med. Biol.* 1981, 59(5-6), 434-40.
- [4] Sjoerdsma, A. Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-α-difluoromethylornithine), an inhibitor of ornithine decarboxylase. *Clin. Pharmacol. Ther.* 1981, 30, 3-8.

- [5] Sjoerdsma, A.; Schechter, P. Difiuoromethylornithine in the treatment of African trypanosomiasis. *Clin. Pharmacol. Ther.* 1984, 35, 287-90.
- [6] Eperon, G.; Balasegaram, M.; Potet, J.; Mowbray, C.; Valverde, O.; Chappuis, F. Treatment options for second-stage gambiense human African trypanosomiasis. *Expert. Rev. Anti. Infect. Ther.* 2014, 12(11), 1407-17.
- [7] Doua, F.; Yapo, F.B. Human trypanosomiasis in the Ivory Coast: therapy and problems. *Acta. Trop.* 1993, 54(3-4), 163-8.
- [8] McCann, P.P.; Pegg, A.E. Ornithine decarboxylase as an enzyme target for therapy. *Pharmacol. Ther.* 1992, 54(2), 195-215.
- [9] Pepin, J.; Milord, F.; Guern, C.; Schechter, P.J. Difluoromethylornithine for arseno-resistant Trypanosoma brucei gambiense sleeping sickness. *Lancet.* 1987, 2(8573), 1431-3.
- [10] Sjoerdsma, A.; Schechter, P.J. Effornithine for African sleeping sickness. *Lancet.* 1999, 354(9174), 254.
- [11] Wolf, J.E.; Jr. Shander, D.; Huber, F.; Jackson, J.; Lin, C.S.; Mathes, B.M.; Schrode, K. Eflornithine HCl Study Group. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. *Int. J. Dermatol.* 2007, 46(1), 94-8.
- [12] Pépin, J.; Mpia, B.; Iloasebe, M. Trypanosoma brucei gambiense African trypanosomiasis: differences between men and women in severity of disease and response to treatment. *Trans. R. Soc. Trop. Med. Hyg.* 2002, 96(4), 421-6.
- [13] Cohen, J.L.; Ko, R.J.; Lo, A.T.; Shields, M.D.; Gilman, T.M. High-pressure liquid chromatographic analysis of Eflornithine in serum. J. Pharm. Sci. 1989, 78(2), 114-6.
- [14] Huebert, N.D.; Schwartz, J.J.; Haegele, K.D. Analysis of 2-difluoromethyl-DL-ornithine in human plasma, cerebrospinal fluid and urine by cation-exchange high-performance liquid chromatography. J. Chromatogr. A. 1997, 762(1-2), 293-8.
- [15] Kilkenny, M.L.; Slavik, M.; Riley, C.M.; Stobaugh, J.F. Plasma analysis of α-difluoromethylornithine using pre-column derivatization with naphthalene-2,3-dicarboxaldehyde/CN and multidimensional chromatography. *J. Pharm. Biomed. Anal.* 1998, 17(6-7), 1205-1213.
- [16] Jansson-Löfmark, R.; Römsing, S.; Albers, E.; Ashton, M. Determination of effornithine enantiomers in plasma by precolumn derivatization with o-phthalaldehyde-N-acetyl-Lcysteine and liquid chromatography with UV detection. *Biomed. Chromatogr.* 2010, 24(7), 768-73.
- [17] Yang, S.; Peng, K.W. Wang, M.Z. A simple and sensitive assay for the effornithine quantification in rat brain using precolumn erivatization and UPLC-MS/MS detection. *Biomed. Chromatogr.* 2015, 29(6), 918-24.
- [18] Hanpitakpong, W.; Kamanikom, B.; Banmairuroi, V.; Na-Bangchang, K. High-performance liquid chromatographic method for determination of 2-difluoromethyl-DL-ornithine in plasma and cerebrospinal fluid. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci. 2003, 788(2), 221-31.
- [19] Sankar, RS. Text book of pharmaceutical analysis, 3 ed. Tirunelveli: *Rx Publications* 2001, 21-3.